Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH ALL 2021 | Current trials of non-cytotoxic therapies for older ALL

Selina Luger • 14 May 2021
ESH ALL 2021
Acute Lymphoblastic Leukemia Leukemia Blinatumomab Dasatinib Hyper-CVAD Inotuzumab ozogamicin Venetoclax

Selina Luger, MD, University of Pennsylvania, Philadelphia, PA, gives an update on current trials investigating the effectiveness of non-cytotoxic therapies for treating elderly patients with acute lymphoblastic leukemia (ALL). These therapies include inotuzumab, venetoclax, blinatumomab and dasatinib. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.

More from Selina Luger

5:22
Determining the optimal dose of induction therapy for patients with AML
Selina Luger • 6 Oct 2022
5:16
Approaches to and the use of MRD in ALL
Selina Luger • 6 Oct 2022
5:05
Determining the most suitable consolidation therapies for AML by defining patient risk group
Selina Luger • 6 Oct 2022
2:14
Challenges in the management of older ALL patients
Selina Luger • 14 May 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals